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ABSTRACT 
Background:	Fibromyalgia	(FM)	is	a	common	and	debilitating	disorder	for	which	there	are	currently	no	treatments	available	that	are	satisfyingly	effective.	Cognitive	behavior	therapy	(CBT)	might	be	a	promising	treatment	option,	but	most	CBT	studies—evaluating	various	multi-component	protocols—have	rendered	mixed	results.	Exposure	therapy	has	shown	some	promise	in	treating	other	chronic	pain	conditions,	but	has	not	been	evaluated	specifically	for	patients	with	FM.	The	general	aim	of	this	PhD	project	was	to	develop	and	evaluate	an	exposure	therapy	protocol	for	FM.	More	specifically,	the	aims	were	to	investigate:		
• The	acceptability	and	efficacy	of	internet-delivered	exposure	therapy	for	FM	(Study	I	and	II).		
• The	cost-effectiveness	of	the	treatment	(Study	III).		
• Potential	mediators	of	treatment	effect	(Study	IV).		
Methods:	Acceptability,	preliminary	efficacy	and	health	economic	effects	of	the	treatment	was	investigated	in	an	open	pilot	study	(Study	I).	The	efficacy	of	the	treatment	was	evaluated	in	a	randomized	controlled	trial,	where	participants	were	randomized	to	either	internet-delivered	exposure	therapy	(iExp)	or	a	waitlist	control	(WLC)	(Study	II).	Participants	were	individuals	18-65	who	had	received	a	FM	diagnosis	from	a	physician	and	who	self-referred	to	participate	in	the	studies.	Primary	outcome	was	FM	symptoms,	and	secondary	outcomes	included	fatigue,	disability,	quality	of	life,	anxiety,	depression,	insomnia	and	psychological	inflexibility.	The	treatment	consisted	of	10	weeks	of	therapist-supported	exposure	therapy	delivered	on	an	online	platform.	The	cost-effectiveness	of	the	treatment	was	investigated	from	both	a	societal	perspective	and	a	healthcare	unit	perspective	using	data	from	the	randomized	trial	(Study	III).	To	investigate	potential	mediators	of	treatment	effect,	a	mediational	analysis	was	conducted	using	data	from	the	randomized	trial	with	weekly	measurements	of	three	potential	mediators	(FM-related	avoidance	behavior,	mindful	non-reactivity	and	FM-related	worry)	and	treatment	outcome	(FM	symptoms)	(Study	IV).			
Results:	Therapist-supported	exposure	therapy	rendered	acceptable	adherence	and	treatment	completion,	with	over	70%	of	participants	initiating	work	with	exposure	in	both	Study	I	and	II.	Participants	receiving	iExp	had	significantly	lower	FM	symptoms	at	post-treatment,	compared	to	pre-treatment	(Study	I)	and	compared	to	the	WLC	(Study	II),	respectively.	Moderate	within-group	(Study	I)	to	large	between-group	(Study	II)	effect	sizes	favoring	iExp	was	observed	on	the	primary	outcome,	and	significant	improvements	were	also	observed	on	all	secondary	outcomes	(Study	I-II).	All	improvements	were	maintained	at	the	6-	(Study	I-II)	and	12-	(Study	II)	month	follow-up.	iExp	was	highly	cost-effective	compared	to	no	treatment,	with	each	
  
successful	treatment	incurring	a	large	societal	cost	saving	(Study	III).	A	reduction	in	avoidance	behavior	mediated	a	reduction	in	FM	symptoms	for	participants	receiving	iExp	compared	to	participants	in	the	waitlist	group	(Study	IV).		
	
Conclusion:	Overall,	the	studies	in	this	PhD	project	point	to	that	iExp	is	an	acceptable,		effective	and	cost-effective	treatment	for	FM	compared	to	waitlist	control,	and	that	targeting	avoidance	behavior	may	be	important	in	exposure	therapy	for	FM.	Future	studies	are	needed	that	compares	iExp	against	an	active	treatment	control,	and	will	benefit	if	including	competing	mediators	of	a	different	treatment	paradigm.		  
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1 INTRODUCTION Imagine	having	long-lasting	pain	in	multiple	parts	of	your	body	and	feeling	almost	constantly	fatigued.	The	pain	might	move	around	from	day	to	day	and	will	often	intensify	with	cold	weather,	but	is	always	present	one	way	or	another.	Often	of	a	grinding,	dull	nature,	sometimes	sharp	and	burning.	After	a	day	filled	with	more	activity	than	usual	you	might	need	to	stay	in	bed	for	a	whole	day	to	recover.	Imagine	being	overly	sensitive	to	certain	fabrics,	smells,	and	sounds,	and	not	having	slept	well	for	years.	You	have	problems	with	concentration,	finding	words	and	holding	a	conversation.	Imagine	that	normal	touch—like	someone	placing	their	hand	on	your	arm,	or	your	child	giving	you	a	hug—being	so	painful	you	have	to	bite	your	lip.			This	is	reality	for	many	individuals	living	with	fibromyalgia.	In	Sweden,	around	200	000	individuals	have	this	condition,	the	vast	majority	of	which	are	women.	Many	of	them	describe	feeling	poorly	understood	by	their	environment	and	healthcare	personnel.	Due	to	the	absence	of	objective	signs	of	the	disorder,	many	patients	feel	their	complaints	either	are	not	taken	seriously,	or	their	symptoms	not	being	recognized	as	fibromyalgia.	One	may	go	for	years	before	receiving	a	correct	diagnosis.	And	when	you	do,	there	are	no	really	effective	treatments	available.		My	interest	in	fibromyalgia	began	during	the	latter	part	of	the	psychology	program.	I	learned	about	an	exposure-based	therapy	that	had	shown	effective	in	irritable	bowel	syndrome,	and	I	got	curious	whether	the	treatment	could	be	effective	for	also	patients	with	fibromyalgia,	this	puzzling	and	many-faceted	condition.	Together	with	a	fantastic	team	of	researchers	me	and	a	fellow	student	were	able	to	explore	this	as	part	of	our	master’s	thesis.	That	was	the	start	of	the	present	doctoral	project,	and	the	studies	presented	within	this	thesis	show	where	we	have	come	this	far.	The	results	are	limited	by	design	and	method	but	do	point	us	in	in	new	and	exciting	directions.	I	hope	this	thesis	can	inspire	future	research	endeavors.					
Stockholm,	November	2019	
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2 BACKGROUND 
2.1 FIBROMYALGIA 
2.1.1 Clinical characteristics  Fibromyalgia	(FM)	is	a	condition	marked	by	chronic	pain	and	multiple	symptoms	of	both	somatic	and	psychological	nature.	The	predominant	feature	is	widespread	pain,	tenderness	and	stiffness	in	the	muscles,	tendons	and	ligaments,	without	any	demonstrated	tissue	abnormality.	More	specifically	patients	with	FM	have	a	decreased	pain	threshold,	which	means	that	they	display	heightened	pain	responses	to	normally	nonpainful	stimuli	(also	known	as	allodynia)	and	heightened	pain	responses	to	normally	painful	stimuli	(also	known	as	hyperalgesia).1	FM	pain	may	occur	body	wide,	migrate	over	the	body,	or	in	pre-specified	points	on	the	body	particularly	sensitive	to	pressure	(so-called	tender	points).	The	pain	often	varies	from	day	to	day	and	many	patients	report	the	pain	aggravating	by	certain	weather	conditions.2-5	Other	common	features	of	the	disorder	include	fatigue,	sleep	disturbances,	subjective	swelling,	paresthesias,	cognitive	dysfunction,	headaches	and	irritable	bowel	syndrome	(IBS),	depression	and	anxiety.6	These	symptoms	can	often	be	as	disabling	as	the	pain	itself,	and	altogether	FM	constitutes	a	plethora	of	medically	unexplained	symptoms,	not	only	causing	disability,	but	often	also	symptom-related	distress	and	avoidance	of	daily	activities.7,8	Not	surprisingly,	FM	is	associated	with	a	lower	health-related	quality	of	life,	and	the	experience	of	illness	seems	to	be	worse	compared	to	many	other	disorders.1		
2.1.2 Diagnostic criteria There	are	no	confirmatory	biomarkers	or	histological	analysis	available	for	FM,	and	diagnosis	is	therefore	based	on	the	presence	of	FM-like	symptoms*.	The	first	diagnostic	criteria	for	classification	of	FM	were	published	in	1990	by	the	American	College	of	Rheumatology	(ACR),10	and	depended	primarily	on	the	physical	examination	of	tender	points.	However,	the	tender	point	criteria	were	problematic	since	the	examination	turned	out	to	be	unreliable,	with	many	physicians	either	not	performing	it	or	doing	it	incorrectly.	Situations	arose	where	patients	who	had	once	fulfilled	the	criteria	but—due	to	fluctuation	in	tender	points	or	measurement	error—failed	to	satisfy	the	criteria	during	a	later	examination.	Also,	in	the	1990	version	there	were	no	criteria	for	other	symptoms	most	commonly	associated	with	FM	such	as	sleep	disturbances,	fatigue	or	cognitive	dysfunction.		Due	to	the	problems	stated	above,	updated	criteria	were	published	in	2010/2011	where	the	tender	point	examination	was	omitted,	and	a	further	revision	published	in	
	
*Of	note,	skeptical	voices	have	also	been	raised	regarding	the	diagnostic	label	of	FM	and	the	very	existence	of	the	disorder.1,9	
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201611	added	a	generalized	pain	criterion.	Diagnostic	criteria	for	FM	now	incorporate	key	symptoms	of	the	disorder	besides	widespread	pain,	provide	severity	scales	for	widespread	pain	and	somatic	symptoms,	and	excludes	other	somatic	conditions	that	sufficiently	explain	the	symptoms†.	However,	the	2016	criteria	have	not	gained	full	impact	in	either	clinical	practice	or	within	the	research	field.	In	Sweden	the	majority	of	patients	are	still	diagnosed	according	to	the	ACR	1990	criteria	within	the	healthcare	system.	To	summarize,	there	is	still	no	internationally	accepted	definition	of	FM.	
2.1.3 Prevalence, comorbidity and health economic aspects Most	prevalence	studies	estimate	the	prevalence	of	FM	to	between	2%	and	4%.12	However,	the	majority	of	prevalence	studies	are	based	on	the	ACR	1990	criteria	which	have	shown	to	yield	lower	prevalence	rates	than	the	modified	2010	criteria,13,14	indicating	that	FM	might	be	more	common	than	previously	thought.	Women	seems	to	be	more	afflicted	than	men,	although	when	using	the	later	version	of	the	criteria	(i.e.,	without	tender	point	examination)	the	sex	ratio	seems	to	be	more	equal,1	however	still	with	a	predominance	in	women.	Although	being	most	common	in	patients	over	50	years	of	age,12	FM	also	occurs	in	children	and	adolescents.15	FM	has	a	high	degree	of	comorbidity.	Common	co-occurring	conditions	are	found	within	the	cardiovascular	and	respiratory	diseases	and	other	pain-related	conditions,16	and	FM	patients	also	display	a	high	rate	of	anxiety	and	depressive	disorders.17	Several	of	these	disorders	(e.g.,	chronic	fatigue	syndrome,	temporomandibular	disorder,	IBS,	migraine)	have	overlapping	symptoms	such	as	generalized	pain	sensitivity,	and	no	consistent	demonstrated	tissue	abnormality.	Observations	from	genetic	research	demonstrating	that	these	syndromes	run	in	families	suggest	that	they	share	heritable	pathophysiologic	features.18,19	 FM	is	also	a	costly	disorder.	Patients	with	FM	on	average	have	a	mean	healthcare	cost	that	is	almost	three	times	higher	than	comparison	patients.16	Being	the	chronic	pain	condition	with	the	highest	rates	of	sick-leave,	unemployment,	claims	for	incapacity	benefits	and	work	absenteeism,	FM	incurs	high	costs	also	on	a	societal	level.20,21			
	
†Diagnostic	criteria	according	to	the	2016	revisions	to	the	2010/2011	criteria.11	(1) Generalized	pain,	defined	as	pain	in	at	least	4	of	5	regions,	is	present.		(2) Symptoms	have	been	present	at	a	similar	level	for	at	least	3	months.		(3) Widespread	Pain	Index	(WPI)	≥	7	and	Symptom	Severity	Scale	(SSS)	score	≥	5	OR	WPI	of	4–6	and	SSS	score	≥	9.	(4) A	diagnosis	of	fibromyalgia	is	valid	irrespective	of	other	diagnoses.	A	diagnosis	of	fibromyalgia	does	not	exclude	the	presence	of	other	clinically	important	illnesses.	
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2.2 ETIOLOGY AND CONTRIBUTING FACTORS Available	evidence	suggests	that	FM	does	not	have	a	clear	etiology	but	may	be	caused	by	multiple	interacting	factors,	including	neurotransmitter-	and	cytokine	imbalances	in	the	central	nervous	system	(CNS),22	disturbances	in	the	hypothalamic–pituitary–adrenal	axis,23	genetic	factors24	and	psychiatric	comorbid	conditions.23	Thus,	there	seems	to	be	many	roads	that	can	lead	to	the	development	of	FM.	As	for	the	question	regarding	what	FM	actually	‘is’,	the	leading	pathophysiological	hypothesis	is	that	FM	is	a	disorder	within	the	CNS	related	to	pain	transmission	and	pain	processing1	and	that	the	CNS	has	a	leading	role	in	the	augmentation	and	amplification	of	pain	in	FM.		The	International	Association	for	the	Study	of	Pain	(IASP)	defines	pain	as	“an	unpleasant	sensory	and	emotional	experience	associated	with	actual	or	potential	tissue	damage,	or	described	in	terms	of	such	damage”.25	This	definition	highlights	the	inherent	subjective	nature	of	pain	and	fits	well	with	the	medically	unexplained	pain	that	is	the	core	feature	of	FM.	It	is	also	well	known	that	the	experience	of	pain	is	a	complex	interaction	of	biological,	psychological	and	social	factors.26	This	is	further	highlighted	below.	
2.2.1 Pain physiology in FM When	pain	occurs	as	a	consequence	of	clear	tissue	damage	or	inflammation,	signals	from	nociceptors	(pain	neurons)	are	transported	via	nerve	cells	to	the	dorsal	horn	in	the	spinal	cord,	from	which	the	information	are	further	transferred	to	the	brain.	Interestingly,	the	brain	can	also	receive	pain	signals	with	only	little	or	even	without	nociceptive	information,	meaning	that	the	patient	experiences	pain	without	tissue	damage	or	inflammatory	processes.27	This	is	the	case	in	FM	and	other	functional	pain	disorders	such	as	IBS,	functional	abdominal	pain	or	chronic	cardiac	chest	pain.	The	incoming	pain	signal	may	be	amplified	or	inhibited,	resulting	in	an	augmented	or	attenuated	pain	perception.1	In	FM,	it	seems	that	the	CNS	itself	contributes	to	an	active	amplification	of	sensory	stimuli,28,29	leading	to	an	enhanced	response	to	noxious	stimuli	as	well	as	an	intensified	excitability	of	the	neurons	in	the	spinal	cord	transmitting	nociceptive	information	to	the	brain.30	Also,	blunting	of	the	descending	inhibitory	pathways	in	FM	attenuates	the	capacity	for	the	CNS	to	achieve	brain-regulated	inhibition	of	pain	signals.31-34		Various	psychological	factors	are	also	involved	in	the	process	of	pain	amplification.	For	instance,	depressive	mood	and	anxiety	are	factors	that	have	been	shown	to	amplify	the	nociceptive	signals	in	experimental	pain.35	Also,	avoidance	behaviors	and	hypervigilance	are	two	factors	that	are	relevant	in	the	understanding	of	FM	(further	elaborated	below).		
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2.2.2 Two psychological factors relevant for FM 
2.2.2.1 Avoidance	behaviors	From	an	evolutionary	perspective,	avoidance	is	a	logical	response	to	pain.	With	pain	being	an	important	warning	signal	about	potential	tissue	damage,	avoidance	behaviors	such	as	avoiding	stimulation	or	physical	activity	will	promote	the	early	healing	process	in	acute	pain.36	However,	when	pain	has	become	chronic,	although	avoidance	behaviors	might	involve	a	short-term	decrease	in	symptoms	or	symptom-related	distress,	they	do	not	lead	to	long-term	improvement	and	may	therefore	be	viewed	as	a	maladaptive	response.37	The	involvement	of	intermittent	short-term	reduction	of	symptoms	and/or	distress	promotes	the	maintenance	of	avoidant	behavior,	and	may	explain	why	it	is	a	common	feature	in	the	symptomatology	of	chronic	pain	conditions.37-39	Importantly,	several	studies	point	to	avoidance	behaviors	as	a	maintaining	and	even	exacerbating	factor	of	pain	intensity,	hypervigilance	towards	bodily	symptoms,	disability	and	psychological	distress,	as	well	as	pain	catastrophizing	(i.e.,	the	tendency	to	interpret	pain	as	highly	threatening)	in	patients	with	chronic	pain	conditions.40-44	Avoidance	behaviors	in	chronic	pain	have	a	diverse	topography.	The	most	obvious	are	overt	(i.e.,	visible	to	others)	behaviors	serving	to	relieve,	control	or	avoid	pain	and	other	aversive	symptoms,	such	as	using	short-term	analgesics,	daytime	resting	or	avoiding	certain	pain-eliciting	situations.	However,	avoidance	behaviors	can	also	be	of	subtle	nature,	such	as	doing	certain	activities	in	a	different	manner	or	with	an	aid,	over-activity	(i.e.,	“biting	the	bullet”),	pacing	activity	or	mental	strategies	(e.g.,	distraction‡,	worry/rumination	or	thought	suppression)	to	reduce	pain	or	pain-related	distress.40,43,44,46-48	Notably,	with	FM	comprising	a	wide	range	of	debilitating	symptoms,	not	only	pain	is	a	possible	focus	of	avoidance.	The	studies	in	the	present	thesis	therefore	define	avoidance	behavior	as	any	overt	or	covert	behavior	that	serves	the	primary	function	to	relieve	or	avoid	FM	symptoms	or	acute	distress	associated	with	FM.	
2.2.2.2 Hypervigilance		Like	avoidance	behaviors,	attention	to	pain	is	a	normal	and	evolutionary	valuable	process	in	cases	of	acute	pain	(i.e.,	it	is	functional	to	attend	to	potential	threats	in	the	environment).	One	of	the	first	discussions	of	excessive	attention	to	pain49	defined	hypervigilance	as	a	perceptual	habit	of	scanning	the	body	for	somatic	sensations,	brought	on	by	a	tendency	to	appraise	bodily	sensations	as	threatening.		Self-reported	high	attention	to	pain	has	been	associated	with	higher	pain	intensity,	emotional	distress	and	psychosocial	disability,	and	to	be	a	significant	predictor	of	disability,	distress	and	healthcare	utilization	regardless	of	pain	intensity.46	Moreover,		
‡Distraction	has	also	been	assumed	to	lessen	pain,45	which	may	explain	why	some	CBT	protocols	for	FM	promote	distraction	as	a	pain	coping	strategy.	
  7	
hypervigilance	as	a	maintaining	factor	in	chronic	pain	has	been	subject	to	empirical	investigation,50,51	and	patients	with	FM	have	been	shown	to	display	higher	vigilance	to	pain52,53	and	other	noxious	stimuli53	than	other	chronic	pain	patients.	One	hypothesis	is	that	FM	would	involve	a	generalized	pattern	of	hyper-responsiveness	to	internal	and	external	discomfort,54,55	that	is,	not	only	pain	but	other	noxious	stimuli	as	well.	Others	claim52	that	hypervigilance	neither	is	an	abnormal	individual	characteristic,	nor	unique	for	FM,	but	highly	depending	on	the	threat	value	of	pain.	Support	for	this	notion	is	the	finding	that	hypervigilance	was	mediated	by	pain	intensity	and	catastrophic	thinking	about	pain,	in	both	FM	patients	and	patients	with	low	back	pain.52			
2.3 PSYCHOLOGICAL THEORIES OF PAIN AND FM Interactions	between	pain	perception	and	-processing,	avoidance	behaviors	and	hypervigilance	to	bodily	symptoms	can	be	understood	within	psychological	theoretical	theories.	With	learning	theory	as	a	base,	the	fear	and	avoidance	model	(FA	model)	and	acceptance	and	commitment	therapy	(ACT)	are	described	below.	The	theories	are	overlapping	and	may	all	contribute	to	the	understanding	of	partial	maintenance	of	symptoms	and	severity	in	FM.		Learning	theory	stipulates	that	behaviors	are	learned	via	respondent	and	operant	conditioning	and	social	learning.	In	respondent	conditioning,	a	neutral	stimulus	(NS)	is	paired	with	an	unconditioned	stimulus	(US),	where	the	US	naturally	and	automatically	elicits	an	unconditioned	response	(UR).	After	the	NS	has	been	associated	with	US	it	becomes	a	conditioned	stimulus	(CS),	that	alone	elicits	the	now	conditioned	response	(CR).56	In	chronic	pain,	the	CR	is	often	distress,	annoyance	or	fear.	Operant	learning	prescribes	that	reinforcement	of	a	behavior	increases	its	future	probability,	and	punishment	decreases	it.57	In	chronic	pain,	avoidance	behaviors	in	chronic	pain	are	hypothesized	to	be	maintained	by	(negative)	reinforcement,	while	non-pain	behaviors	are	extinguished	by	nonreinforcement	(e.g.,	the	pleasure	of	the	behavior	outweighed	by	its	cost	in	terms	of	increased	symptoms)	or	punishment	(e.g.,	increased	pain).	A	potent	reinforcer	of	avoidance	behaviors	is	short-term	symptom	reduction	(i.e.,	pain,	fatigue,	stiffness),	as	well	as	reduction	of	the	conditioned	response	(e.g.,	distress,	annoyance	and	fear).	From	a	learning	theory	perspective,	hypervigilance	lowers	the	threshold	for	detecting	aversive	symptoms,	which	may	further	amplify	this	learning	process.46	One	psychological	model	that	has	applied	learning	theory	to	chronic	pain	and	extended	with	cognitive	theory	is	the	fear	and	avoidance	model	(FA	model).39	According	to	the	FA	model,	pain	experience	after	an	injury	can	be	interpreted	as	either	dangerous	or	harmless.	When	pain	is	perceived	as	non-threatening,	rapid	confrontation	with	daily	activities	is	likely	to	occur,	leading	to	recovery.	In	catastrophizing	patients,	pain-related	fear	activates	avoidance	behavior	and	hypervigilance,	leading	to	functional	disability,	
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disuse	and	depression.	The	latter	will	in	its	turn	maintain	the	pain	experience,	further	fueling	a	vicious	cycle	of	fear	and	avoidance.	A	revised	version	of	the	FA	model58	also	acknowledges	the	importance	of	valued	goals	in	relation	to	pain-related	avoidance.		Originally	developed	for	low-back	pain	the	FA	model	stipulates	that,	for	fearful	patients,	pain-related	fear	cognitions	are	the	maintaining	factor	of	chronic	pain.	Indeed,	there	are	studies	showing	that	catastrophizing	is	associated	with	increased	disability,	pain	intensity	and	decreased	pain	threshold.59-61	However,	the	FA	model	was	never	intended	to	explain	all	cases	of	chronic	pain,	62	and	may	not	be	as	applicable	to	generalized	pain	disorders	such	as	FM.58	Firstly,	avoidance	may	also	be	elicited	without	the	conscious	feeling	of	fear,	for	instance	as	a	habitual	response.63,64	Secondly,	chronic	pain	can	elicit	a	multitude	of	negative	emotions	besides	fear	(e.g.,	annoyance,	frustration	and	sadness),	all	of	which	can	become	conditioned	and	trigger	avoidance	behaviors.	Thirdly,	not	all	patients	with	chronic	pain	display	overt	pain-related	avoidance,	but	respond	to	pain	with	excessive	activity65-67(so-called	pain-persistence	patterns	or	endurance-related	responses68,69).	Prospective	studies	show	that	endurance	behavior	is	a	significant	predictor	of	pain	intensity.70,71	Thus,	although	the	FA	model	is	relevant	for	many	patients	with	pain	and	FM,	complementary	approaches	are	also	needed.		Another	development	within	learning	theory	of	chronic	pain	is	acceptance	and	
commitment	therapy	(ACT).	According	to	ACT	theory,	human	suffering	can	be	explained	by	the	human	unwillingness	to	experience	negative	thoughts,	emotions	and	bodily	sensations	(e.g.,	pain).	This	so-called	experiential	avoidance	leads	to	a	narrow	and	inflexible	behavioral	repertoire	and	the	individual	becoming	increasingly	separated	from	important	life	values,	aggravating	disability	and	impairing	quality	of	life.72	
Psychological	flexibility	is	a	construct	that	can	be	viewed	as	the	opposite	to	experiential	avoidance,	and	may	be	defined	as	actively	embracing	aversive	inner	experiences	when	they	occur	as	ongoing	inner	experiences,	and	to	engage	in	activities	guided	by	one’s	goals,	while	in	the	presence	of	those	inner	experiences.	One	aspect	of	psychological	flexibility	is	acceptance—that	is,	to	allow	unwanted	private	experiences	to	come	and	go	without	trying	to	alter	them.	Pain	acceptance	have	been	shown	to	be	associated	with	less	pain,	pain-related	anxiety	and	avoidance,	distress	and	disability73,74	and	greater	psychological	well-being75	in	chronic	pain	patients.	In	FM,	pain	acceptance	has	been	shown	to	be	associated	with	less	FM	severity,	anxiety	and	depression,	as	well	as	better	general	health	and	functioning.76			
2.4 TREATMENT OF FM 
2.4.1 Non-psychological treatments The	pharmacological	agents	most	thoroughly	evaluated	for	treating	FM	include	antidepressants	such	as	amitriptyline,	duloxetine	and	milnacipran,	and	the	antiepileptic	
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agent	pregabalin/gabapentin.77	These	drugs	have	shown	to	have	positive	effects	not	only	on	pain	but	also	on	secondary	symptom	domains	in	FM.78	However,	the	observed	effect	sizes	of	these	drug	treatments	are	mostly	modest	and	tolerability	is	often	limited	by	side	effects.	Overall,	the	benefits	of	pharmacotherapy	in	FM	have	been	argued	to	be	of	limited	clinical	relevance.77,79		Also,	a	broad	range	of	other	non-pharmacological	treatments	have	been	evaluated	for	FM.	Examples	include	(but	are	not	restricted	to)	physical	exercise,	balneotherapy,	body	awareness	therapy,	biofeedback,	complementary/alternative	medicine	(CAM)	treatments	(e.g.,	acupuncture,	chiropractic	therapy,	homeopathy,	massage	therapy,	meditative	moment	therapies	or	mind/body-therapies),	trans-magnetic	stimulation	and	trans-direct	current	stimulation.80	A	recent	meta-analysis80	concluded	that	exercise	and	meditative	moment	therapies	may	be	beneficial	for	FM	patients.	However,	studies	are	generally	too	small	and	of	insufficient	quality,	why	no	definitive	conclusions	regarding	the	benefits	of	these	treatments	can	be	made.79,80	
2.4.2 Psychological treatments The	majority	of	psychological	treatments	evaluated	for	FM	have	been	varieties	of	cognitive	behavior	therapy	(CBT),	described	below.	Additional	psychological	interventions	evaluated	for	FM	include	mindfulness-based	interventions,81,82	short-term	psychodynamic	therapy83	and	hypnosis.84	Apart	for	a	few	exceptions	(e.g.,	attention	modification	training85)	most	of	these	studies	have	had	null	findings	or	modest	effects.	
2.4.3 Cognitive behavior therapies CBT	is	the	most	evaluated	psychological	treatment	for	FM,86	with	over	40	randomized	clinical	trials.	Apart	from	a	few	studies	(e.g.,87-90),	results	between	trials	have	been	mixed	with	mostly	small	to	moderate	effects.	The	varying	results	could	possibly	be	due	to	methodological	issues	such	as	differences	in	sample	size	and	type	of	intervention(-s).	For	instance,	the	majority	of	these	studies	have	evaluated	multi-component	protocols	consisting	of	a	combination	of	CBT	interventions,	such	as	cognitive	restructuring,	problem-solving	techniques,	relaxation,	patient	education,	stress-	and	self-management.91	Despite	the	many	evaluations	of	CBT	for	FM,	only	two	trials	have	investigated	what	actually	drives	the	treatment	effects	(i.e.,	mediators).92,93	Additionally,	there	is	little	evidence	regarding	the	cost-effectiveness	of	CBT	for	FM.94-97		
2.4.3.1 Exposure	therapy	Being	one	of	the	central	interventions	in	CBT,	exposure	constitute	the	main	component	in	CBT	protocols	for	various	anxiety	disorders98-104	and	have	also	been	successfully	evaluated	for	some	somatic	conditions.105-107	In	essence,	exposure	therapy	involves	repeated	and	sustained	contact	with	stimuli	that	elicit	symptom-related	distress.	This	can	be	done	by	systematic	exercises	in	which	the	patient	provokes	aversive	and/or	
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feared	bodily	symptoms	(interoceptive	exposure),	approach	avoided	situations	(in-vivo	exposure)	or	imagine	fearful	or	painful	memories,	feelings	or	thoughts	(imaginative	exposure).	Exposure	also	involves	refraining	from	so-called	safety	behavior	to	reduce	anxiety	or	distress	(i.e.,	a	subtle	form	of	avoidance	behavior).	The	central	process	of	improvement	in	exposure	is	not	established,	but	hypotheses	include	an	increased	tolerance	for	fear	and	distress,	as	well	as	the	patient	gaining	new	information	on	being	able	to	cope	with	the	stimuli,	situations	and	symptoms.108				With	avoidance	behaviors	and	hypervigilance	acknowledged	as	contributing	factors	in	chronic	pain,	exposure	has	been	proposed	as	a	reasonable	intervention38,39.	Indeed,	exposure	in	vivo	have	been	evaluated	in	a	few	clinical	trials,109-112	and	two	trials	have	investigated	ACT	(which	also	has	a	major	focus	on	exposure)	for	FM.89,93	Although	some	of	these	exposure	in	vivo	trials	have	also	included	FM	patients,	none	has	investigated	exposure	therapy	specifically	on	an	FM	population.	Findings	pertaining	to	other	chronic	pain	conditions	(e.g.,	low	back	pain)	cannot	necessarily	be	generalized	to	FM,	since	patients	with	FM	differs	from	the	larger	chronic	pain	population,	not	least	by	displaying	a	multitude	of	other	symptoms.				The	treatment	manual113	in	previous	trials	evaluating	exposure	in	vivo	all	build	on	the	FA	model.	The	main	component	is	exposure	in	vivo	exercises,	mainly	targeting	overt	avoidance	behaviors	derived	from	the	patient’s	ratings	on	a	questionnaire114	assessing	the	threat	value	of	various	physical	movements	from	daily	life.	In	contrast,	a	treatment	that	comprise	also	interoceptive	exposure	(i.e.,	actively	provoking	FM	symptoms)	could	possibly	be	more	effective	in	reducing	symptom-related	distress.	Also,	a	functional	view	on	avoidance	(capturing	also	covert	avoidance,	as	well	as	avoidant	behavior	related	to	other	FM	symptoms	than	pain	only)	should	theoretically	be	able	to	target	an	increased	number	of	relevant	avoidance	behaviors.	
2.4.3.2 Internet-delivered	CBT	Internet-delivered	CBT	(internet-CBT)	is	an	online-based	treatment,	designed	and	structured	to	promote	the	same	behavioral	changes	as	in	traditional	face-to-face	CBT.	The	patient	takes	part	of	self-help	material	and	works	with	CBT	exercises	and	strategies,	guided	by	an	identified	therapist	who	gives	feedback	and	answers	questions.115	Internet-CBT	has	been	shown	to	be	as	effective	as	traditional	face-to-face-therapy	for	a	number	of	somatic	and	psychiatric	conditions.116		Internet	as	treatment	modality	may	be	beneficial	for	several	reasons	when	evaluating	a	novel	treatment	protocol.	First,	as	internet-CBT	demands	less	time	per	patient	from	the	therapist,	it	is	possible	to	conduct	a	relatively	large-scale	clinical	trial	with	little	resources,	increasing	statistical	power	to	detect	meaningful	differences.	Also,	with	the	patient	not	being	tied	to	attend	scheduled	meetings	at	a	clinic	national	recruitment	is	possible,	generating	a	larger	population	to	the	sample	and	thereby	increasing	the	
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generalizability	of	any	potential	findings.	Second,	the	treatment	content	is	highly	structured,	which	minimizes	the	risk	of	treatment	contamination	due	to	non-adherence	from	the	therapist.	In	other	words,	internet-CBT	allows	the	treatment	content	to	be	more	to-the-point	by	eliminating	non-specific	treatment	factors,	which	enables	the	isolation	and	investigation	of	potentially	effective	treatment	components.117		Internet-CBT	could	also	be	a	suitable	treatment	modality	for	the	FM	population,	as	treatment	participation	does	not	require	scheduled	meetings	at	a	clinic	which,	due	to	symptom	fluctuation,	could	be	a	problem	in	FM.	Instead,	the	patient	works	with	the	treatment	in	her	own	pace,	repeating	the	treatment	content	whenever	necessary.	With	the	access	to	CBT	treatment	being	generally	low,118	internet-CBT	may	also	enhance	the	access	to	a	potentially	effective	treatment.	Internet-CBT	for	FM	with	therapist	support	has	previously	been	investigated	in	two	trials,119,120	both	using	traditional	CBT	protocols,	with	mixed	results.	Hence	there	is	a	gap	of	knowledge	regarding	the	acceptability	and	efficacy	of	exposure	therapy	for	FM	in	internet	format.		
2.5 SUMMARY OF THE BACKGROUND OF THE THESIS FM	is	a	prevalent	and	disabling	condition.	It	is	associated	with	low	quality	of	life	and	high	comorbidity	with	other	conditions,	and	is	also	a	costly	disorder	for	both	healthcare	providers	and	society.	Most	likely	the	etiology	of	FM	is	multifactorial,	i.e.,	many	roads	can	lead	to	the	development	of	FM.	Avoidance	behaviors	and	hypervigilance	are	probably	important	and	interacting	psychological	mechanisms	in	the	maintenance	of	chronic	widespread	pain,	the	main	feature	of	FM.		Altogether	the	available	evidence	suggests	that	CBT	might	have	the	potential	to	alleviate	FM	symptoms.	However,	the	overall	between-group	effect	sizes	are	low	and	the	health	economic	aspects	of	this	treatment	is	still	unclear.	Additionally,	we	still	do	not	know	what	drives	the	treatment	effect	in	the	different	CBT	protocols.	Thus,	there	is	still	a	need	for	large-scale	clinical	trials	designed	to	take	the	first	steps	in	investigating	mechanisms	and	mediators	of	treatment	outcome	in	CBT	for	FM.	Internet-CBT	could	increase	outreach	to	patients	with	FM	but	the	evidence	of	this	treatment	format	is	still	limited.			Exposure	is	a	potentially	promising	treatment	strategy,	but	a	new	approach	compared	to	previous	trials	might	yield	better	results.	A	functional	view	on	avoidance,	acknowledging	that	additional	symptoms	besides	pain	can	elicit	symptom-related	avoidance,	and	targeting	also	covert	avoidance;	open	up	for	identifying	more	relevant	avoidance	behaviors	to	target	in	treatment.				 	
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3 AIMS The	overall	aim	of	the	thesis	was	to	develop	and	evaluate	an	internet-delivered	exposure-based	treatment	for	FM.	The	premise	was	to	explore	whether	exposure	to	stimuli	associated	with	FM-related	distress	as	well	as	avoided	situations	and	activities	would	be	beneficial	for	patients	with	FM.	Specific	aims	and	hypotheses	for	each	study	are	presented	below:	
3.1 STUDY I The	aim	of	the	first	study	was	to	develop	a	first	version	of	the	treatment	protocol	and	to	evaluate	the	acceptability,	efficacy	and	health	economic	effects	of	an	internet-delivered	exposure-	and	acceptance-based	treatment	for	FM.		
3.2 STUDY II This	study	aimed	to	revise	the	treatment	protocol	and	evaluate	the	efficacy	of	internet-delivered	exposure	therapy	(iExp)	compared	to	a	waitlist	control	group	within	a	randomized	controlled	trial.	Based	on	the	results	from	Study	I,	we	hypothesized	that	the	treatment	would	be	more	effective	than	the	control	group.	
3.3 STUDY III Study	III	used	data	from	Study	II,	and	aimed	to	evaluate	the	treatment’s	cost-effectiveness	and	cost-utility.	We	hypothesized	that	iExp	would	be	cost-effective	compared	to	a	waitlist	control.	
3.4 STUDY IV Study	IV	used	data	from	Study	II,	and	sought	to	investigate	possible	mediators	of	treatment	outcome.	We	hypothesized	that	FM-related	avoidance	behaviors,	FM-related	worry	and/or	mindful	non-reactivity	would	mediate	a	change	in	FM	symptoms	for	participants	receiving	iExp	compared	to	participants	in	the	waitlist	control	group.	
  13	
4 EMPIRICAL STUDIES 
4.1 DESIGNS, ASSESSMENTS, ANALYSES 
Study	I	was	an	open	pilot	study	where	41	participants	received	internet-delivered	exposure-	and	acceptance-based	CBT.	Main	outcome	was	severity	and	impact	of	FM	symptoms,	measured	by	The	Fibromyalgia	Impact	Questionnaire	(FIQ),121	and	secondary	outcomes	included	fatigue,	anxiety,	depression,	insomnia,	psychological	inflexibility,	pain	disability,	and	health-related	quality	of	life.	Treatment	acceptability	was	operationalized	as	having	completed	all	introductory	parts	of	the	treatment	and	initiated	work	with	exposure.	Assessments	were	made	online	at	pre-treatment,	weekly	during	treatment,	post-treatment	and	at	6-months	follow-up.	Within-group	effects	were	tested	with	paired	t-tests	to	estimate	whether	changes	from	pre-	to	post-treatment	and	from	pre-treatment	to	6-months	follow-up	were	statistically	significant.	Effect	sizes	were	calculated	using	Cohen’s	d122	(i.e.,	the	standardized	mean	difference	between	two	values),	where	meaningful	differences	have	been	suggested	to	be	d=0.2	(small),	d=0.5	(moderate)	and	d=0.8	(large).	
Study	II	was	a	randomized	controlled	trial	using	waitlist	as	control,	where	140	participants	were	randomized	on	a	1:1	ratio	to	either	internet-delivered	exposure	therapy	(iExp)	or	to	a	waitlist	control	group	(WLC).	The	primary	outcome	was	identical	to	Study	I,	and	secondary	outcomes	included	fatigue,	anxiety,	depression,	insomnia,	disability,	quality	of	life	and	psychological	inflexibility.	Assessments	were	made	online	at	pre-treatment,	weekly	during	treatment,	post-treatment,	and	for	the	treatment	group	also	at	6-	and	12-months	follow-up.	Participants	on	WLC	were	offered	treatment	after	post-treatment	assessment	was	completed.	Efficacy	was	analyzed	on	an	intention-to-treat	basis	using	mixed	effects	modelling	to	estimate	if	there	was	a	significant	time*group	interaction	effect	on	change	from	pre-	to	post-treatment.	Effect	sizes	were	calculated	using	Cohen’s	d122.	
Study	III	was	a	health-economic	evaluation	of	the	iExp	treatment	and	used	data	from	Study	II.	Data	was	collected	at	pre-	and	post-treatment	and	at	12-month	follow-up	(treatment	group	only,	as	the	waitlist	group	were	crossed	over	to	treatment	after	10	weeks).	Costs	for	healthcare	consumption	and	productivity	loss	was	collected	using	a	cost	diary,123	and	analyzed	in	relation	to	outcome	(i.e.,	treatment	responder	defined	as	reliable	change	on	FIQ,	and	also	quality-adjusted	life	years	(QALYs)	using	EQ-5D.124	We	used	national	tariffs	to	estimate	costs	for	health	care	visits,	and	productivity	losses	were	estimated	using	gross	earnings	data	from	each	participant.	Cost-effectiveness	comparisons	were	analyzed	using	incremental	cost-effectiveness	ratios	(ICERs),	defining	the	cost	for	one	additional	treatment	responder	when	offered	iExp	instead	of	WLC,	as	well	as	the	net	benefit	approach	with	different	willingness-to-pay	(WTP)	scenarios.	We	analyzed	cost-effectiveness	both	from	a	societal	perspective	(including	all	direct	and	indirect	costs)	as	well	a	healthcare	unit	perspective	(which	included	
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only	direct	treatment	costs).	All	analyses	were	made	according	to	the	intention-to-treat	principle.	
Study	IV	was	a	mediation	analysis	using	data	from	Study	II.	Proposed	mediators	were	FM-related	avoidance	behaviors,125	mindful	non-reactivity126	and	FM-related	worry,127	and	outcome	was	FM	symptoms.121	Assessments	were	made	online	at	pre-treatment,	post-treatment	and	weekly	during	treatment	on	both	mediators	and	outcome.	Univariate	and	multivariate	models	were	used	to	estimate	the	direct	effect	of	the	treatment,	as	well	as	the	indirect	effects	of	the	proposed	mediators;	on	the	outcome.	A	time-lagged	analysis	was	made	to	confirm	unidirectionality,	that	is,	that	a	change	in	the	mediator	predicted	a	change	in	the	outcome	and	not	vice	versa.			
4.2 PARTICIPANTS All	participants	in	Study	I-IV	were	18-65	years	old,	self-referred,	had	daily	access	to	internet	and	confirmed	having	received	a	FM	diagnosis	from	a	physician.	In	Study	I,	advertisements	were	posted	on	a	FM	patient	association	website,	an	online	discussion	forum	for	CBT	therapists	and	a	website	containing	information	on	internet	interventions.	In	Study	II,	information	was	also	spread	through	social	media	and	advertising	in	a	national	newspaper.	All	studies	included	participants	from	all	of	Sweden,	of	which	almost	all	were	women	(100%	vs.	98%).	The	mean	age	ranged	between	50.3	to	52	years	and	the	majority	(63%	vs.	66%)	had	commenced	college	or	university	education.	Participants	had	on	average	had	their	FM	diagnosis	for	between	9	to	10	years	when	entering	the	study,	although	the	mean	duration	of	FM	symptoms	was	considerably	longer	(15—17.5	years).			
4.3 THE INTERVENTION 
4.3.1 Study I The	intervention	in	the	pilot	study	was	based	on	an	internet-CBT	manual	for	IBS128	and	an	ACT	manual	for	face-to-face	group	treatment	for	FM.93	The	treatment	was	delivered	via	a	secure	internet	platform,	with	self-help	texts,	images,	and	worksheets.	The	10-week	treatment	consisted	of	five	consecutive	modules	to	which	the	participant	got	gradual	access	by	completing	homework	assignments.	The	main	intervention	was	exposure	to	stimuli	associated	with	FM-related	distress,	such	as	FM	symptoms	and	avoided	situations	and	activities.	Exposure	exercises	were	based	on	the	participant’s	FM-related	avoidance	behaviors	as	well	as	their	identified	life	values.	These	were	both	mapped	by	the	participant	in	the	first	treatment	module,	setting	the	stage	for	behavioral	change,	and	participants	were	encouraged	to	try	and	carry	out	both	types	of	exposure	during	treatment.	Exposure	exercises	involved	provoking	FM	symptoms,	approach	
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avoided	situations	and	activities,	and	refraining	from	avoidance	behaviors.	A	lot	of	emphasis	was	put	on	explaining	the	treatment	rationale,	in	which	the	role	of	avoidance	behavior	in	maintaining	and	exacerbating	FM	symptoms	was	stressed	(see	Figure	1,	the	maintenance	model).			
	
. 	To	increase	the	ability	to	stay	present	in	exposure	exercises	with	one’s	full	attention	(i.e.,	to	refrain	from	covert	avoidance	behaviors	such	as	distraction),	participants	were	encouraged	to	practice	neutral	labelling	of	symptoms.	Participants	were	taught	a	10-minute	self-observation	exercise	to	practice	once	daily,	involving	observing	and	labelling	the	breath,	interoceptive	sensations	and	thoughts,	and	the	external	environment.	Moreover,	participants	were	taught	a	shorter	version	where	instructions	were	to	pause	the	current	activity	for	a	short	while,	then	observe	their	bodily	sensations	for	a	short	while,	then	continue	as	before.	An	additional	short	exercise	was	also	presented,	tailored	to	be	used	in	situations	when	experiencing	distressful	symptoms.	Participants	were	also	introduced	to	exercises	in	how	to	loosen	entanglement	from	negative	thoughts	(also	known	as	decentering	or	cognitive	defusion).		Each	participant	was	assigned	a	therapist	whose	main	function	was	to	encourage	any	progress	made	in	the	treatment,	support	the	participant	in	finding	individual	exposure	exercises,	answer	questions	and	help	problem-solve	when	needed.	Therapist	contact	consisted	of	written	messages	within	the	treatment	platform,	and	additional	telephone	calls	were	used	if	the	participant	needed	further	support.	Any	participants	who	lagged	behind	were	reminded	by	their	therapist	through	platform-delivered	mobile	text	messages	and	phone	calls.	The	web	platform	also	contained	a	closed	discussion	forum	where	participants	could	discuss	their	treatment	with	each	other.	
Figure 1. Screenshot of the maintenance model.
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4.3.2 Lessons learned from Study I The	starting	point	of	this	PhD	project	was	to	investigate	whether	patients	with	FM	could	benefit	from	a	treatment	focusing	on	decreasing	symptom-specific	avoidance	behaviors	and	hypervigilance	through	systematic	exposure.	We	originated	from	a	manual	that	has	shown	effective	in	IBS,105,106,128-130	a	condition	highly	comorbid	with	FM.	Early	on	we	decided	to	incorporate	elements	from	ACT	as	we	hypothesized	that	certain	ACT	interventions	(e.g.,	focusing	on	life	values)	would	increase	motivation	to	engage	in	behavior	change.		The	lessons	drawn	from	Study	I	was	that	many	participants	were	in	fact	positive	to	behavior	change	using	a	more	traditional	rationale	for	exposure	(i.e.,	using	a	maintenance	model	similar	to	the	one	used	in	the	manual	for	IBS).	Also,	a	challenge	emerged	in	delivering	the	rationale	for	values-based	action.	Several	participants	experienced	problems	in	identifying	important	life	values	and	deriving	valued	activities	that	were	independent	of	their	FM.	One	possible	explanation	could	be	that	the	introduction	to	and	exercise	in	identifying	and	mapping	life	values	were	in	the	first	module	of	treatment,	i.e.,	at	a	time	when	they	were	just	getting	acquainted	with	the	treatment	context	and	format,	and	with	a	dense	amount	of	other	concurrent	psychoeducational	material.	It	is	probably	a	fair	estimate	that	this	intervention,	when	not	delivered	within	a	full	ACT	context	(i.e.,	with	complementing	facilitating	interventions)	might	not	have	achieved	its	full	potential.		Moreover,	the	therapists	in	Study	I	found	a	challenge	in	motivating	the	participants	to	conduct	exposure	using	two	partly	differing	rationales.	In	values-based	exposure,	participants	were	first	encouraged	to	join	in	values-based	behavioral	activation,	and	later	on	to	engage	in	values-based	exposure	exercises.	In	contrast,	when	conducting	exposure	as	prescribed	originally	in	the	IBS-manual,	exercises	were	derived	from	the	participants’	symptom-specific	avoidance	behavior.	Consequently,	exercises	were	not	necessarily	associated	with	life	values	(although,	of	course,	they	could	be),	but	rather	with	the	emphasis	to	try	to	challenge	as	many	avoidance	behaviors	as	possible.	Although	the	purpose	was	to	provide	a	broader	perspective	on	behavioral	change	by	offering	two	related	yet	complementary	approaches	to	exposure,	the	impression	from	the	therapists	was	that	most	participants	found	this	confusing.		
4.3.3 Study II In	Study	II	the	number	of	modules	were	extended	to	eight,	with	three	modules	assigned	to	different	aspects	of	exposure.	Exposure	exercises	were	derived	only	from	FM-related	avoidance	behaviors,	i.e.,	overt	and	covert	avoidance	behaviors	with	the	function	to	relieve	FM	symptoms	and	FM-related	distress.	These	were	mapped	by	the	participant	in	a	behavior	diary	in	the	first	three	modules	of	the	treatment.	Participants	were	encouraged	to	go	full	throttle	in	their	exposure,	albeit	concurrently	emphasizing	autonomy	and	control.	In	essence,	our	message	to	the	participant	was:	We	suggest	you	
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go	all	in	on	these	exposure	exercises	and	challenge	yourself	‘to	the	max’.	However,	it	is	you	
who	are	in	the	driving	seat	here	and	you	can	do	it	any	way	you	want.	Only	you	can	adapt	
these	principles	to	your	own	life.	In	contrast	to	Study	I,	the	concept	of	life	values	was	not	introduced	until	the	end	of	treatment,	as	part	of	the	relapse	prevention	and	maintenance	of	gains.	The	rationale	of	the	self-observation	exercise	was	somewhat	extended	in	that	it	was	presented	as	an	extra	suitable	exercise	for	participants	who	identified	that	they	tended	to	respond	to	pain	with	pain-persistent	behaviors.	Homework	reports,	worksheets	and	images	were	also	revised.	There	was	no	discussion	forum	in	Study	II.			
	
 
 
4.4 SAFETY PARAMETERS Severe	psychiatric	conditions	requiring	immediate	intervention	were	ruled	out	before	inclusion,	via	an	online	screening	procedure	as	well	as	a	clinical	intake	interview	with	a	psychology	graduate	student	under	supervision	or	a	clinical	psychologist.	Participants	that	were	excluded	due	to	severe	depression	or	suicidal	ideation	were	recommended	to	seek	regular	psychiatric	services.	
Figure 2. Exposure worksheet in Study II. 
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In	both	Study	I	and	II,	all	participants	were	assessed	weekly	regarding	suicidal	ideation.	Any	participant	scoring	≥4	on	the	suicide	item	on	the	Montgomery-Åsberg	Depression	Rating	Scale-self	report	(MADRS-S)131	were	phoned	by	their	therapist,	who	conducted	a	comprehensive	assessment	of	immediate	suicide	risk.	If	deemed	necessary,	a	crisis	plan	was	established	together	with	the	participant.	Adverse	Events	(AE)	were	collected	in	Study	I	and	II.	Questions	regarding	AEs	were	collected	at	post-treatment,	6-	and	12-months	follow-up	(the	latter	with	Study	II	only),	with	detailed	follow-up	questions	on	any	possible	event.	All	AEs	were	assessed	by	a	clinical	psychologist,	and	if	needed	followed-up	with	a	telephone	interview.			
4.5 ETHICAL CONSIDERATIONS The	majority	of	patients	with	FM	are	treated	with	pharmacological	agents,	although	often	with	insufficient	effects	and	with	more	or	less	severe	side	effects.	Finding	new	treatments	is	therefore	of	great	importance.	Comorbidity	is	high,	both	regarding	somatic	and	psychiatric	conditions,	thus	this	is	a	vulnerable	patient	group	with	an	overall	broad	and	pronounced	suffering.	This	presents	the	research	group	with	a	variety	of	ethical	aspects	on	patient	safety	when	conducting	studies	investigating	novel	treatments.	Several	ethical	considerations	have	been	taken	into	account	in	this	PhD-project.		First,	the	fact	that	many	patients	with	FM	have	cognitive	difficulties	(e.g.,	concentration	problems,	memory	deficits	and	difficulty	carry	on	conversations—often	by	patients	themselves	referred	to	as	‘fibro-fog’),	had	bearings	on	several	areas	in	the	studies.	One	such	area	is	assessment	of	the	competence	of	understanding	patient	information	and	giving	informed	consent.	To	ensure	that	the	participants	voluntarily	agreed	to	participate	in	the	research,	the	assessing	psychologist	(or	psychology	graduate	student)	in	Studies	I	and	II	informed	the	participants	what	they	may	expect	if	they	choose	to	participate	in	the	study	and	of	their	right	to	discontinue	treatment	at	any	time.	This	information	was	provided	in	both	verbal	and	written	form	and	contact	information	was	given	in	case	of	questions	or	uncertainties.	Participants	who	expressed	difficulties	reading	or	understanding	the	self-help	texts	were	offered	extra	support	by	their	therapist	via	telephone.	Another	related	issue	is	the	weekly	assessments,	implying	an	extra	burden	for	participants	suffering	from	heavy	fatigue	and	cognitive	deficits.	To	address	this	issue,	we	put	a	lot	of	effort	in	selecting	short	questionnaires,	to	keep	the	total	number	of	items	relatively	low	while	at	the	same	time	maximizing	patient	safety	and	the	quality	of	the	data.	All	measures	were	collected	using	an	assessment	tool	that	securely	stores	sensitive	data	in	accordance	with	applicable	rules	and	regulations.	Second,	online-delivered	treatment	can	theoretically	pose	a	challenge	in	how	to	detect	any	sudden	deterioration	in	mental	health	since	there	is	no	face-to-face	contact.	
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However,	the	possibility	of	having	online	contact	several	times	per	week,	and	the	weekly	assessment	of	symptoms	(including	suicidal	ideation)	provides	the	participant	and	therapist	an	opportunity	to	detect	deterioration	in	physical	or	mental	health	that	is	not	possible	in	usual	healthcare,	where	the	patient	usually	meets	with	the	therapist	only	once	a	week	without	any	contact	in-between	sessions.	Third,	to	ensure	the	integrity	of	the	participants	the	treatment	was	provided	on	an	encrypted	web	platform,	accessed	by	participants	and	therapists	via	a	two-factor	authentication.	Personalized	passwords	were	confirmed	via	text	messages	to	the	participant’s	and	therapist’s	mobile	phones.		Finally,	all	studies	were	reviewed	and	approved	by	the	Regional	Ethics	Review	Board	in	Stockholm,	Sweden,	and	the	clinical	Studies	I	and	II	were	also	registered	in	the	ClinicalTrials.gov	trial	registry.	To	summarize;	when	weighing	the	need	of	developing	more	effective	treatments	for	FM	with	the	need	of	safety	and	integrity	of	the	individual,	we	were	able	to	include	participants	that	have	few	other	effective	treatment	options,	regardless	of	where	they	live	in	Sweden	and	with	the	opportunity	to	intense	therapist	contact.	The	study	design	with	a	large	sample	that	enables	high	power	and	a	highly	structured	treatment,	enabled	good	conditions	for	answering	the	research	questions.			 	
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5 RESULTS 
5.1 STUDY I 
Internet-Delivered	Acceptance	and	Values-Based	Exposure	Treatment	for	
Fibromyalgia:	A	Pilot	Study.	Post-treatment	assessments	were	completed	by	40	out	of	41	participants	(98%).	Significant	improvements	were	seen	at	all	outcomes	from	pre-	to	post-treatment	(all	ps	<.001),	and	from	pre-treatment	to	follow-up	(all	ps	<.001).	A	moderate	within-group	effect	size	was	observed	on	the	primary	outcome	(d=0.71;	95%	CI	0.46	to	0.91)	at	post-treatment,	and	looking	from	pre-treatment	to	follow-up	the	effect	size	was	large	(d=0.96;	95%	CI	0.66	to	1.27).	Thirty	out	of	41	participants	commenced	work	with	exposure,	indicating	that	the	treatment	was	acceptable.	There	were	significant	cost	reductions	both	at	post-treatment	(p=.002)	and	at	follow-up	(p=.04)	compared	to	pre-treatment.	
5.2 STUDY II 
Internet-based	Exposure	Therapy	for	Fibromyalgia:	A	Randomized	Controlled	
Trial.	All	participants	completed	the	primary	outcome	at	pre-	and	post-treatment	assessments.	On	the	primary	outcome	there	was	a	significant	interaction	effect	of	group	and	time	with	a	large	between-group	effect	size	(d=0.90;	95%	CI	0.55	to	1.24),	favoring	the	treatment	group.	In	the	iExp	group,	44%	of	the	participants	achieved	a	reliable	improvement	on	the	primary	outcome.	Significant	improvements	were	also	seen	on	all	secondary	outcomes,	the	majority	with	moderate	to	large	effect	sizes	(d=0.44	to	1.24).	All	effects	were	stable	at	6-	and	12-month	follow-up.	Treatment	adherence	was	high,	with	74%	of	the	participants	initiating	work	with	exposure.		
5.3 STUDY III 
Cost-Effectiveness	and	Cost-Utility	of	Internet-Delivered	Exposure	Therapy	for	
Fibromyalgia:	Results	From	a	Randomized,	Controlled	Trial.	iExp	was	found	to	be	highly	cost-effective	compared	to	WLC,	as	shown	by	a	greater	total	cost	reduction	at	post-treatment	(-5,097;	95%	[CI	-9,337	to	-857];	p=.018).	Cost	differences	between	iExp	and	WLC	were	primarily	driven	by	a	lower	cost	of	work	cutback	in	the	iExp	group.	From	a	societal	perspective	the	ICER	was	estimated	to	-5,025/.33=-$15,295,	meaning	there	was	a	cost	reduction	of	-US$15,295	for	each	additional	responder	to	iExp	treatment.	From	a	healthcare	unit	perspective,	the	corresponding	figure	was	726/.33=$2,211.	Two	sensitivity	analyses	showed	that	iExp	would	remain	cost-effective	also	when	assuming	markedly	higher	intervention	costs.			
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The	cost-effectiveness	of	iExp	seemed	to	be	driven	partly	by	decreases	in	direct	medical	and	indirect	non-medical	costs	in	the	iExp	group,	but	also	by	an	increase	in	direct	non-medical	costs	in	the	waitlist	group.	Analyses	of	dose-response	relationships	revealed	that	participants	who	made	a	reliable	improvement	(i.e.,	a	reliable	decrease	on	FIQ)	from	pre-	to	post-treatment	had	significantly	lower	costs	post-treatment	and	correspondingly,	participants	who	made	a	reliable	deterioration	(i.e.,	a	reliable	increase	on	FIQ)	had	higher	costs	post-treatment.	Analyzing	the	iExp	group	from	post-	to	follow-up	showed	that	a	clinical	deterioration	was	associated	with	significantly	higher	costs	of	sick-leave	at	follow-up.		
5.4 STUDY IV 
Approach	As	a	Key	for	Success:	Reduced	Avoidance	Behaviour	Mediates	the	Effect	
of	Exposure	Therapy	for	Fibromyalgia	iExp	significantly	predicted	decrease	in	FM	symptoms,	consistent	with	the	results	in	Study	II.	In	the	multivariate	model,	all	proposed	mediators	were	significant	mediators	of	exposure	therapy	on	FM	symptoms.	In	the	multiple	mediation	model,	the	mediators	together	explained	60%	of	the	treatment	effect,	of	which	FM-related	worry	emerged	as	the	strongest	mediator.	However,	in	the	time-lagged	analyses,	only	FM-related	avoidance	behavior	displayed	a	unidirectional	relationship	over	time	with	FM	severity,	whereas	for	mindful	non-reactivity	and	FM-related	worry	the	relationship	was	bidirectional.				 	
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6 DISCUSSION Our	findings	suggest	that	internet-delivered	exposure	therapy	is	an	acceptable	treatment	for	patients	with	FM	that	is	significantly	better	than	no	treatment	in	reducing	FM	symptoms	as	well	as	all	secondary	outcomes.	The	treatment	also	seems	to	be	highly	cost-effective,	with	each	successfully	treated	participant	resulting	in	a	large	societal	cost	reduction,	and	appears	to	achieve	its	effect	by	a	reduction	in	FM-related	avoidance	behaviors.	The	findings	are	discussed	below.		
6.1 IS INTERNET-DELIVERED EXPOSURE THERAPY ACCEPTABLE AND 
EFFECTIVE FOR PATIENTS WITH FM? To	answer	this	question	two	studies	were	conducted.	Study	I	involved	the	development	of	the	treatment	manual	and	evaluation	of	its	acceptability	and	preliminary	efficacy.	Study	II	began	with	an	in-depth	inventory	of	experiences	from	therapists	and	participants	from	Study	I,	which	lay	the	foundation	for	an	extensive	revision	of	the	treatment	manual.	The	updated	version,	which	focused	solely	on	exposure	based	on	FM-related	avoidance	behaviors,	was	evaluated	regarding	efficacy	and	long-term	effects	in	a	randomized	controlled	trial.		In	both	Studies	I-II,	73—74%	of	participants	initiated	work	with	exposure,	indicating	that	they	found	the	treatment	acceptable.	Also,	data	attrition	was	low	in	both	studies,	implying	that	participants	in	general	were	not	too	burdened	by	the	weekly	online	assessments.		Comparing	results	from	Study	I	and	II	to	earlier	trials	on	CBT	for	FM,	the	within-group	effects	seen	in	Study	I	were	higher	than	those	reported	in	a	review	on	psychological	treatments	for	FM.132	Moreover,	the	between-group	effect	sizes	on	pain	intensity	(d=0.86),	fatigue	(d=0.88)	and	disability	(d=0.91)	in	Study	II	is	higher	than	the	corresponding	mean	between-group	effect	sizes	reported	in	a	meta-analysis	on	CBT	trials	for	FM	(pain	intensity	d=0.29,	fatigue	d=0.27,	disability	d=0.43),91	but	with	a	therapist	time	of	only	175	minutes	for	a	whole	treatment.	However,	the	studies	included	in	this	meta-analysis91	used	various	control	conditions	(of	which	treatment-as-usual	was	the	dominant	one),	thus,	comparisons	should	be	made	bearing	this	in	mind.	Results	from	Study	II	was	also	slightly	higher	than	the	between-group	effect	sizes	reported	by	other	studies	on	fatigue,	sleep	problems	and	the	risk	difference	(RD)	in	attaining	≥50%	pain	relief	(RD	0.27)	and	a	≥20%	improvement	of	health-related	quality	of	life	(RD	0.31)	in	a	recent	review	and	meta-analysis	on	internet-delivered	psychological	therapies	for	FM	(≥50%	pain	relief	RD	0.10;	≥20%	improvement	of	health-related	quality	of	life	RD	0.22).133		With	the	exception	of	a	recent	Dutch	study,109	results	from	Study	II	are	also	comparable	to	previous	randomized	controlled	trials	of	exposure	therapy	for	other	chronic	pain	
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conditions	(although	it	should	be	noted	that	the	primary	outcome	in	Study	II	differs	from	previous	trials,	i.e.,	by	also	covering	FM	symptoms	other	than	pain	and	pain-related	disability).	As	described	previously	though,	the	iExp	treatment	manual	differ	from	existing	exposure	protocols	for	chronic	pain.	Whereas	in	previous	trials	exposure	is	aimed	to	target	pain-related	fear,	exposure	according	to	iExp	primarily	targets	the	individual’s	symptom-specific	avoidance	behaviors,	and	also	acknowledges	and	emphasizes	the	role	of	covert	avoidance	behaviors.	The	regular	structured	training	in	observing	and	labelling	aversive	bodily	sensations	might	have	helped	the	participants	to	identify	and	prevent	subtle	or	covert	avoidance	behaviors,	thereby	facilitating	the	effects	of	exposure.	In	addition,	the	fact	that	iExp	exercises	also	comprised	interoceptive	exposure	(i.e.,	actively	provoking	aversive	bodily	symptoms)	might	have	helped	to	decrease	symptom-related	distress.	Whether	the	results	would	be	comparable	with	the	treatment	delivered	in	a	face-to-face	setting	remains	an	empirical	question.	However,	the	variability	and	constant	fluctuation	of	symptoms	in	FM	could	pose	a	risk	of	cancelled	appointments	in	face-to-face	therapy,	and	the	flexibility	attained	with	internet	as	treatment	modality	may	therefore	be	beneficial	for	this	patient	group.	Furthermore,	internet-CBT	enables	patients	in	rural	areas	to	access	treatment,	where	availability	to	CBT	therapists	is	mostly	scarce.118	Nonetheless,	internet	as	treatment	modality	is	a	restraining	factor	regarding	generalizability,	since	many	patients	with	FM	suffer	from	cognitive	difficulties134,135	and	thus	migh	perceive	the	amount	of	reading	as	too	demanding.	Internet-delivered	therapy	is	probably	suitable	for	a	subgroup	of	FM	patients,	while	others	might	benefit	more	from	a	face-to-face	format.	All	the	while,	if	some	patients	with	FM	can	be	successfully	treated	with	internet-delivered	therapy,	this	could	help	relieve	the	patient	burden	on	the	healthcare	system	and	thus	facilitate	a	more	efficient	use	of	healthcare	resources.		So,	yes	-	internet-delivered	exposure	therapy	is	acceptable	and	effective	for	a	self-referred	sample	of	FM	patients	when	evaluated	against	a	waitlist	control,	with	promising	results	on	several	outcomes	compared	to	the	majority	of	CBT	protocols	previously	evaluated	for	this	condition.		
6.2 IS EXPOSURE THERAPY FOR FM COST-EFFECTIVE? We	hypothesized	that	iExp	would	be	cost-effective	as	we	assumed	that	the	effects	gained	would	outweigh	the	additional	costs	of	a	low-resource	treatment	of	internet-	CBT.	The	results	indeed	supported	our	hypothesis.	iExp	was	not	only	cost-effective,	but	cost	saving.	For	every	successful	treatment	(i.e.,	a	treatment	responder)	instead	of	a	participant	on	waitlist,	there	was	a	societal	cost	saving	of	US$15,295.	iExp	had	a	100%	probability	of	being	cost-effective	using	a	societal	perspective,	even	with	a	WTP-scenario	of	$0.		
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The	results	from	Study	III	confirms	the	cost	reductions	observed	in	Study	I,	and	are	also	in	line	with	other	cost-effectiveness	analyses	from	other	internet-delivered	psychological	interventions.136	The	findings	from	Study	III	also	extend	previous	findings	regarding	cost-effectiveness	on	CBT	for	FM	by	including	symptom-specific	as	well	as	generic	outcomes,	providing	an	estimate	of	the	treatment	costs	also	in	relation	to	improvement	of	FM	symptoms	in	addition	to	QALYs	gained.	Dose-response	analyses	also	indicate	that	clinical	gains	were	associated	with	decreases	in	societal	costs.			
6.3 CAN WE IDENTIFY VARIABLES THAT MEDIATE TREATMENT 
OUTCOME?  With	Study	II	being	the	first	evaluation	of	exposure	therapy	for	FM,	and	with	a	new	treatment	manual	than	in	previous	trials	investigating	exposure	for	other	chronic	pain	conditions,	the	choice	of	mediators	in	Study	IV	was	explorative.	Since	previous	mediation	studies	from	CBT92	and	ACT93	treatment	for	FM,	as	well	as	exposure	therapy	for	IBS,137,138		points	in	a	direction	where	a	decrease	in	avoidance	mediates	outcome,	we	aimed	to	include	mediators	that	functionally	capture	different	aspects	of	avoidance.			A	somewhat	unexpected	finding	was	that	only	FM-related	avoidance	behavior	displayed	a	unidirectional	relationship	over	time	with	FM	symptoms,	whereas	the	two	other	proposed	mediators	seem	to	be	bidirectionally	related	to	treatment	outcome.	Notably,	all	three	mediators	were	significant	in	both	the	univariate	and	multivariate	mediation	analysis,	implying	that	the	establishment	of	temporality	is	an	important	feature	when	investigating	treatment	mediators.	The	results	in	Study	IV	are	in	line	with	previous	findings,92,93,137,138	and	thus	add	to	the	growing	body	of	research	supporting	avoidance	behavior	as	an	important	treatment	target	in	exposure	treatment	for	chronic	pain	conditions.	The	findings	are	scientifically	relevant	not	only	as	they	provide	support	for	the	theoretical	underpinnings	of	exposure	(i.e.,	learning	theory),	but	also	since	relatively	few	studies	has	been	dedicated	to	the	nature	of	avoidance	behavior	in	chronic	pain	compared	to	e.g.	pain-related	fear.139	From	a	clinical	view,	the	finding	that	reducing	avoidance	behavior	are	key	for	a	successful	treatment	outcome	in	exposure	therapy	might	be	informative	to	clinicians.	In	addition,	the	fact	that	the	results	favor	the	utility	of	exposure	as	a	treatment	for	FM	could	be	motivating	for	patients.			
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6.4 GENERAL METHODOLOGICAL ISSUES 
6.4.1 On pain-related fear The	studies	in	the	present	thesis	did	not	have	fear	of	pain	or	movement	as	an	inclusion	criterion,	as	opposed	to	previous	trials	of	exposure	therapy	for	chronic	pain109-112	where	participants	were	included	based	on	assessments	on	fear	of	pain	(as	measured	by	Photograph	Series	Of	Daily	Activities,	PHODA114)	or	movement	(as	measured	by	Tampa	Scale	for	Kinesiophobia140).	Contrary	to	these	studies,	the	treatment	model	used	in	the	present	thesis	does	not	stipulate	fear	per	se	to	be	the	fueling	factor	in	the	maintenance	process,	partly	because	it	is	our	clinical	impression	that	many	patients	with	FM	generally	do	not	identify	with	being	fearful	of	pain	or	movement.	Furthermore,	a	post-hoc	regression	analysis	using	baseline	value	of	pain-related	distress	(measured	with	Pain	Reactivity	Scale,	PRS127)	and	pre-to	post	change	on	FIQ	showed	that	pain-related	distress	at	baseline	did	not	predict	treatment	outcome	(p=.93,	unpublished	data).	Nevertheless,	since	previous	studies	show	a	relationship	between	pain-related	fear	and	pain	outcomes,59-61	the	studies	in	the	present	thesis	should	ideally	have	included	a	widely	used	measure	of	pain-related	fear	or	pain	catastrophizing	(e.g.,	Pain	Anxiety	Symptoms	Scale-short	version,	PASS-20141	or	Pain	Catastrophizing	Scale,	PCS142)	to	investigate	its	role	in	relation	to	the	effects	of	iExp.		
6.4.2 iExp vs ACT – the same treatment? Some	might	argue	that	the	iExp	and	ACT	share	so	many	characteristics	that	the	similarities	overcome	the	differences.	This	is	a	fair	question	and	warrants	a	discussion.		As	previously	described,	the	manual	in	Study	I	stemmed	partly	from	an	ACT	protocol	and	thus	bear	several	elements	of	ACT.	Although	the	treatment	manual	was	extensively	revised	in	Study	II,	iExp	and	ACT	do	still	share	several	treatment	features.	Exposure,	self-observation	exercises	and	strategies	to	promote	cognitive	entanglement	are	critical	parts	in	both	protocols.	Both	iExp	and	ACT	acknowledge	overt	as	well	as	covert	avoidance	behaviors	as	important	treatment	targets.	Nonetheless	I	would	argue	that	the	treatments	also	appear	quite	distinct	from	one	another,	that	is,	in	terms	of	what	is	delivered	to	the	patient	and	how	this	is	framed.	One	particular	aspect	that	distinguish	the	treatments	is	the	rationale	for	exposure.	In	ACT,	the	concept	of	life	values	plays	an	important	role	and	exposure	focuses	on	behavioral	change	in	line	with	personal	life	values.	Consequently,	participants	are	instructed	to	derive	exposure	exercises	from	one’s	identified	life	values.	The	central	message	to	the	patient	is	that	exposure	aims	to	aid	the	patient	into	living	a	life	with	more	purpose	and	meaning	in	the	presence	of	pain	and	suffering.	In	iExp,	the	key	message	to	the	patient	is	that	structured	and	repeated	exposure	teaches	the	brain	to	be	less	hyper-reactive	to	pain,	which	thereby	might	lead	to	a	decrease	intensity	of	symptoms	and	symptom-related	distress.	The	patients	derive	suitable	exposure	exercises	from	the	identified	symptom-specific	avoidance	behaviors.	That	is,	iExp	do	not	emphasize	the	importance	of	basing	exposure	on	important	life	
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values,	but	rather	merely	‘for	the	sake	of	it’	to	maximize	future	behavioral	flexibility.	For	the	same	reason,	participants	are	encouraged	to	go	‘full	throttle’	in	their	exposure.	The	role	of	life	values	had	a	more	retracted	role	in	iExp,	introduced	at	the	end	of	treatment	as	part	of	maintenance	of	gains	and	relapse	prevention.	The	difference	in	rationales	for	exposure	is	closely	related	to	another	central	distinction	between	iExp	and	ACT,	namely	the	desired	treatment	outcomes.	Whereas	ACT	aims	for	a	valued	living	via	values-driven	behavior,143	iExp	aims	for	reduction	of	FM	symptoms.	Regardless	of	the	various	similarities	and	dissimilarities	of	iExp	and	ACT,	the	active	treatment	mechanism	could	potentially	still	be	the	same	in	the	two	treatments.	This	warrants	more	attention	in	future	research.			
6.5 VALIDITY AND GENERALIZABILITY OF RESULTS Undoubtedly	the	main	factor	affecting	the	generalizability	of	the	results	from	the	studies	in	the	present	thesis	is	the	use	of	a	waitlist	control	in	Study	II.	That	is,	comparisons	to	other	clinical	trials	should	be	made	bearing	in	mind	that	a	waitlist	control	provides	an	advantageous	comparison	for	the	treatment	under	investigation	(i.e.,	inflating	any	favorable	differences	between	the	treatment	group	and	the	control	group).	Also,	without	an	active	treatment	control,	causal	inferences	on	potential	active	treatment	components	should	be	made	with	caution.		The	use	of	self-referral	in	Studies	I	and	II	suggest	that	participants	might	have	been	more	motivated	and	open	to	psychological	treatment,	or	relatively	less	disabled	-	or	both	-	than	a	clinical	sample	recruited	from	a	tertiary	pain	clinic.	Moreover,	the	sample	in	the	current	study	was	relatively	well	educated,	with	35%	stating	≥3	years	of	college	or	university	education.	Post-hoc	analyses	showed	that	level	of	education	(on	a	7-point	Likert	scale)	did	not	predict	treatment	outcome	(defined	as	pre-	to	post	change	score	on	FIQ)(p=.43	[regression	analysis]	vs	p=.39	[non-parametric	trend	test],	unpublished	data),	although	it	should	be	noted	that	this	might	reflect	a	low	variance	in	the	sample	regarding	this	variable.	Nevertheless,	the	sample	in	Study	II	resembled	those	in	previous	CBT	trials	with	consecutive	clinic	patients	regarding	clinical	characteristics	and	FM	symptoms.91	Thus,	we	do	not	believe	that	the	sample	constitutes	a	severe	outlier	in	terms	of	FM	severity.	As	there	was	no	formal	assessment	of	FM	diagnosis	in	Studies	I-II	we	cannot	be	fully	sure	that	all	participants	had	an	FM	diagnosis.	On	the	other	hand,	since	there	is	yet	no	international	consensus	on	diagnostic	criteria	in	the	clinical	context	the	sample	in	Studies	I-II	probably,	at	least	to	some	degree,	reflect	the	FM	population	seen	in	regular	healthcare.	The	procedure	where	participants	confirm	having	received	a	diagnosis	from	a	physician	has	previously	been	used	successfully	in	several	randomized	controlled	trials	on	CBT	for	adults	with	IBS.105,128,129	In	the	present	PhD	project,	this	approach	
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empowered	a	large-scale	trial	with	participants	from	all	over	Sweden,	generating	well-powered	data	for	a	first	evaluation	of	the	treatment’s	efficacy.		Concerning	the	generalizability	of	the	results	to	other	chronic	pain	conditions,	there	are	no	obvious	reasons	to	believe	that	the	overall	treatment	model	of	iExp	would	not	be	efficacious	for	other	populations	of	chronic	pain.	Notably,	since	the	iExp	manual	is	written	to	be	tailored	to	the	FM	population,	self-help	texts,	case	illustrations	and	worksheet	examples	are	all	written	to	be	identifiable	from	the	perspective	of	an	FM	patient.	Evaluating	iExp	on	a	sample	of	patients	with	i.e.,	low	back	pain,	would	therefore	require	an	extensive	revision	of	the	treatment	manual	regarding	content.	Although	this	remains	an	empirical	question,	a	potential	hypothesis	is	that	the	specific	focus	on	the	symptomatology	and	characteristics	of	FM	might	have	been	experienced	as	positive	by	the	participants,	as	it	might	have	promoted	feelings	of	identification	and	validation.		With	Study	IV	being	an	explorative	investigation	of	mediators	of	outcome,	a	potential	limitation	is	that	we	did	not	include	a	measure	of	hypervigilance	to	pain	as	a	potential	mediator.	Since	hypervigilance	is	a	common	feature	in	patients	with	FM	it	would	have	served	as	a	natural	competitor.	A	more	advanced	statistical	analysis	(i.e.,	structural	equation	modelling)	could	also	have	provided	an	investigation	of	how	the	process	of	excessively	attending	to	bodily	symptoms	relates	to	avoidance	behavior.		
6.6 FUTURE DIRECTIONS The	present	PhD	project	has	enabled	a	first	evaluation	of	internet-delivered	exposure	therapy	for	FM	regarding	acceptability,	efficacy,	cost-effectiveness	and	mediators	of	treatment	outcome.	An	obvious	question	is	how	the	effects	stand	in	comparison	to	an	active	control	group.	A	reasonable	comparator	would	be	a	traditional	cognitive-behavioral	treatment	manual	(e.g.,144),	since	traditional	CBT	is	the	psychological	treatment	that	has	been	most	extensively	investigated	within	FM.	This	would	also	allow	for	analyses	of	long-term	effects	of	iExp	in	relation	to	an	active	control	condition,	including	a	more	in-depth	investigation	of	participants	who	deteriorate	after	treatment,	and	comparing	mediators	from	theoretically	divergent	perspectives.		One	important	issue	for	future	studies	includes	the	development	of	an	instrument	aimed	to	capture	FM-specific	avoidance	behavior.	A	more	to-the-point	estimate	of	overt	as	well	as	covert	avoidant	behavior	would	benefit	both	clinicians	and	patients,	and	could	also	be	of	use	in	future	treatment	outcome	studies	and	mediation	analyses.		Another	construct	to	investigate	as	a	process	measure	is	hypervigilance	to	bodily	symptoms,	for	instance	using	the	Pain	Vigilance	and	Awareness	Questionnaire	(PVAQ).145	Future	studies	could	elucidate	whether	avoidant	behavior	and	hypervigilance	are	independent	or	interdependent	processes.	For	instance,	it	may	be	
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that	hypervigilance	is	closely	correlated	to	avoidance	behavior,	and	that	change	in	hypervigilance	to	bodily	symptoms	due	to	successful	exposure	treatment	is	heavily	dependent	on	change	in	avoidance	behavior.	To	further	advance	the	field,	future	mediation	studies	should	ideally	use	a	design	that	allows	for	experimental	control	over	the	mediators.146	Here,	participants	would	be	randomly	assigned	to	different	treatment	protocols	designed	to	have	a	low,	medium	or	high	influence	on	a	proposed	mediator.	This	design	would	allow	for	a	precise	manipulation	of	the	mediator	and	investigation	if	that	manipulation	was	associated	with	a	subsequent	change	in	FM	symptoms.	Also,	moderated	mediation	could	help	elucidate	whether	the	influence	of	the	mediator/-s	on	treatment	outcome	are	depending	on	certain	variables	(e.g.,	pain-related	fear	or	education	level).		Building	on	knowledge	from	experimental	pain	and	neuroimaging,	future	studies	could	also	investigate	whether	mechanisms	of	pain	processing	and	pain	regulation	respond	to	exposure	therapy.	A	particularly	interesting	question	is	whether	we	can	observe	any	changes	in	patients’	response	to	noxious	stimuli	or	descending	pain	inhibitory	pathways	after	having	received	exposure	therapy,	as	compared	to	baseline.	Using	a	three-armed	design	with	a	WLC	as	well	as	a	group	of	healthy	participants,	specific	dimensions	on	pain	regulation	could	be	targeted	through	validated	batteries	(e.g.,	Quantitative	Sensory	Testing,	QST147)	and	assessed	through	functional	magnetic	resonance	imaging.	This	type	of	study	could	serve	as	an	objective	measure	of	the	treatment’s	effect	and	also	provide	an	attempt	to	better	understand	pathophysiological	processes	in	FM.			  
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7 CONCLUSIONS Internet-delivered	exposure	therapy	is	an	acceptable	and	effective	treatment	for	patients	with	FM.	It	has	the	potential	to	reach	patients	nationwide	for	a	condition	that	has	no	sufficiently	effective	treatment	available.	iExp	is	also	highly	cost-effective	compared	to	no	treatment,	both	for	healthcare	and	for	society	as	a	whole.	Reducing	FM-related	avoidance	behavior	mediates	a	reduction	in	FM	symptoms,	and	challenging	avoidance	may	therefore	be	an	important	target	in	exposure	therapy.	Future	studies	comparing	iExp	to	other	treatments	are	warranted.			  
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